Fig. 2From: Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experiencePSA - scatterplot of cost-effectiveness analysisBack to article page
